Nuvectis Pharma, Inc. (NVCT)

USD 4.7

(-8.02%)

Market Cap (In USD)

90.8 Million

Revenue (In USD)

-

Net Income (In USD)

-22.26 Million

Avg. Volume

97.21 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
4.52-12.1
PE
-
EPS
-
Beta Value
0.404
ISIN
US67080T1088
CUSIP
67080T108
CIK
1875558
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Ron Bentsur M.B.A.
Employee Count
-
Website
https://www.nuvectis.com
Ipo Date
2022-02-04
Details
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.